A Phase 3 interventional study of Cebranopadol in Pain, Neoplasms and Chronic Pain, sponsored by Tris Pharma, Inc.. Completed at 22 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pain with a site in Bulgaria — none open to participants now, none under way, none of them phase 3. Pain · Bulgaria.
Among the 19 studies in Pain with a site in Bulgaria, this one is the 16th largest by enrollment, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 11th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 19 studies in Pain with a site in Bulgaria is open now. The open studies under Pain, anywhere →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 15 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 397 across the 19 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 19 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 7 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Pain with a site in Bulgaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.
The trial consisted of 3 phases: Titration Phase, Maintenance Phase, and Follow-Up. The total duration of the trial was approximately 28 weeks for each individual participant, including the Follow-up. The participants received cebranopadol for a maximum of approximately 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning. Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day.
Drug: Cebranopadol
Film-coated tablet; strengths: 200, 400, or 600 µg
Also known as: GRT6005
Number of Participants With Treatment Emergent Adverse Event (TEAEs)
The safety of cebranopadol was assessed by the number of participants with treatment emergent adverse events (TEAEs). A TEAE was any adverse event that occurred after the first administration of investigational medicinal product (IMP), i.e., cebranopadol in this study. In addition, pretreatment adverse events which worsened during the treatment period were also considered TEAEs.
Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)
Intensity of Treatment Emergent Adverse Events
A Treatment Emergent Adverse Event (TEAE) was defined as any Adverse Event (AE) that occurred on or after the first intake of cebranopadol or a pretreatment AE which worsened during the treatment period. TEAEs were classified by the investigator as falling into 1 of 3 categories: Mild: Signs and symptoms that can be easily tolerated. Symptoms can be ignored and disappear when the participant is distracted. Moderate: Symptoms cause discomfort but are tolerable; they cannot be ignored and affect concentration. Severe: Symptoms which affect usual daily activity. For TEAE where the intensity changed over time, the maximum intensity observed during the whole duration of the adverse event was documented.
Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow-up after the last dose)
Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period
Participants were asked "Please rate your pain by selecting the one number that best describes your pain on average during the last week." and scored their average pain intensity during the last week of the treatment period on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The absolute change from baseline for the average pain intensity during the last week was determined for all participants that scored their pain intensities. A mean value for all participants was calculated.
Time frame: Baseline Visit (Day 1) to End of Treatment Visit (up to 26 weeks).
Outcome of Treatment Emergent Adverse Events (TEAE)
The outcome of a TEAE was classified into 1 of the following 6 categories by the investigator, i.e. * Recovered/Resolved. * Recovered/Resolved with sequelae. * Fatal * Recovering/Resolving. * Not recovered/Not resolved. * Unknown (e.g., because the participant is lost to follow up).
Time frame: Baseline (Day 2) to End of trial (i.e., up to Week 28)
Time to Onset of Treatment Emergent Adverse Events (TEAEs)
The median time, in days, from the start of the open-label cebranopadol treatment to the start day of the treatment emergent adverse event (TEAE).
Time frame: Baseline (Day 2) to End of trial (up to Week 28)
Duration of Treatment Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical occurrence attributed to cebranopadol. Duration of Adverse Event was calculated as stop date minus start date plus 1 for non-missing and partial dates.
Time frame: Baseline (Day 2) to End of trial (up to Week 28)
Causal Relationship of Treatment Emergent Adverse Events (TEAEs)
The causality of TEAEs was assessed by the investigator as falling into 1 of the following 7 categories: Conditional/Unclassified, Unassessable/Unclassifiable, Not related, Unlikely, Possible, Probable/likely, or Certain. The numbers of TEAEs per category are presented.
Time frame: Baseline (Day 2) to End of trial (up to Week 28)
Countermeasures Taken for Treatment Emergent Adverse Events (TEAEs)
The countermeasure of a Treatment Emergent Adverse Event (TEAE) was classified by the investigator as being a study medication-related countermeasure and based on non-study medication countermeasures. Non-study medication related countermeasures were categorized as being one of the following: No countermeasure given; A newly started medication or change in dose or route of application of a concomitant medication due to the AE; Other countermeasures, e.g., physical therapy, surgery. Study medication-related countermeasures were categorized as being one of the following: Dose not changed; Dose reduced; Drug interrupted; Trial discontinuation. Absolute numbers are per category reported.
Time frame: Baseline (Day 2) to End of trial (up to Week 28)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Cebranopadol
Only participants with TEAEs which were assessed by the investigator as falling into one of the 3 categories of causality (Possible, Probable/likely, or Certain) were summarized. The initial breakdown planned based on intensity, outcome, time to onset, duration, and countermeasures was not performed and is therefore not reported.
Time frame: Baseline (Day 2) to End of trial (up to Week 28)
Columbia-Suicide Severity Rating Scale (C-SSRS) Scores
The C-SSRS was administered by a clinician who had been certified to administer the C-SSRS at each visit. Suicidal ideation is classified on a 5-item scale (where 1 = Wish to be dead, 2 = Non-specific active suicidal thoughts, 3 = Active Suicidal Ideation with any methods (not plan) without intent to act, 4 = Active Suicidal Ideation with some intent to act, without specific plan, 5 = Active suicidal ideation with a specific plan and intent). The number of participants with suicidal ideation at baseline is presented below for categories with at least 1 participant.
Time frame: Baseline (Day 1) to End of trial (up to Week 28)
Mean Scores of Chronic Pain Sleep Inventory (CPSI) and Changes From Baseline
The CPSI was completed by the participants. It measures 5 items, all on a 100-mm visual analog scale: Participant's assessment of Sleep Problem Index subscores and need for sleep medication (the lower the score the better): (1) Trouble falling asleep (0 = never; 100 = always); (2) Needing sleep medication to help fall asleep (0 = never, 100 = always); (3) Awakened by pain during the night (0 = never, 100 = always); and (4) Awakened by pain in the morning (0 = never, 100 = always). The Sleep Problem Index is the sum of items (1), (3), and (4) with a maximum score of 100 indicating maximum sleep problems. Participant's assessment of the Overall Quality of Sleep (the higher the score the better): (5) Overall quality of sleep (0 = very poor, 100 = excellent).
Time frame: Baseline (Day 1); End of Treatment (up to Week 26)
Weekly Means of Daily Average Pain Intensity During the First Month of Treatment
Participants were asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning during the first month of treatment (comprising Titration Weeks 1 and 2 and Maintenance Weeks 1 and 2). They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-hour average pain intensity was calculated as a mean score of these daily entries of average pain intensity for each week.
Time frame: Baseline (Day 1); Titration Weeks 1 and 2; Maintenance Weeks 1 and 2
Worst Pain Intensity in the Last Week of Treatment (Week 26)
Participants were asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last week." at some of the visits during the treatment period. They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The mean scores of the worst pain intensity were calculated for all participants. Results for baseline and Week 26 are presented.
Time frame: Baseline (Day 1); End of Treatment (Week 26)
Weekly Average Number of Breakthrough Pain Episodes
The number of episodes of breakthrough pain during the past week was planned to be collected. However, for some participants, the intensity of breakthrough pain for the past week has been collected instead of the incidence of breakthrough pain events. Since the values of the intensity of breakthrough pain were much higher (maximum of up to 99) than the frequency of pain events, the mean is skewed and cannot be interpreted. The median for the weekly average number of breakthrough pain episodes is less influenced by these values and is reported below.
Time frame: Baseline (Day 1); End of Treatment (Week 26)
Mean Scores of Neuropathic Pain Symptom Inventory (NPSI)
Participants with neuropathic pain (determined by the completion of the DN4 \[Douleur Neuropathique\] questionnaire at enrollment) rated their symptoms of neuropathic pain using the NPSI. Ten out of 12 questions (Q1-3, 5, 6, 8-12) are answered on an 11-point numerical scale (NRS) ranging from 0 (no symptom present) to 10 (worst imaginable). The NPSI Total Score was calculated as the sum of the 10 single items scored on the 11-point NRS divided by 100. The mean score is reported on a scale of 0 (no neuropathic pain components present) to 1 (all neuropathic pain components have the maximum imaginable intensity).
Time frame: Baseline (Day 1); Weeks 2, 6, 14, 18; End of Treatment (up to Week 26)
EuroQol-5 Dimension (EQ-5D) Health Status Index Outcome
Participants answered 5 questions on the 5 dimensions of the EuroQol-5 Dimension Health Questionnaire: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D Health Status Index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1), the better the health status.
Time frame: Baseline (Day 1); End of Treatment (up to Week 26)
EuroQol-5 Dimension (EQ-5D) Health Questionnaire - Visual Analog Scale (VAS)
The EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant-rated scale where a single value is ticked for "Your own health state today" on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline (Day 1); End of Treatment (up to Week 26)
Patient Global Impression of Change (PGIC)
In the PGIC, participants indicates the perceived change over the treatment period compared to their condition prior to the start of treatment. Participants are requested to choose 1 of 7 categories. Scores range from "very much improved" to "very much worse". The frequency of responses per category are provided.
Time frame: Baseline (Day 1); End of Treatment (up to Week 26)
Clinical Global Impression of Change (CGIC)
For the CGIC assessment, the clinician indicates the perceived change in the patient's condition over the treatment period as compared to the patient's condition prior to the start of treatment. The clinician is requested to choose 1 of 7 categories. Categories range from "very much improved" to "very much worse".
Time frame: Baseline (Day 1); End of Treatment Visit (up to Week 26)
Use of On-demand Opioid Analgesic Medication
Participants reported the opioid type and amount of an opioid in mg/day used to relieve their breakthrough pain over the time period in the study. The average number of units of on-demand opioid medication administered during the previous day (reported on Day 3) and during the last 3 days (reported at all other visits) were documented. The number of units of on-demand opioid medication administered during the Treatment Period is summarized descriptively over the treatment period.
Time frame: From Day 3 to End of Treatment (up to Week 26) (13 time points)
Mean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol.
For those participants, who received morphine prolonged release in the CORAL trial (KF6005/07, NCT01964378) and were, thus, switched from morphine prolonged release to cebranopadol in the CORAL XT trial, the equianalgesic doses of morphine prolonged release and cebranopadol was identified.
Time frame: Baseline (Day 1); End of first month of treatment
Mean Eastern Cooperative Oncology Group Performance Status (ECOG) Scores
The investigator scores the ECOG performance status for a participant on a 6-point categorical scale as follows: * 0 indicates that a participant is "fully active, able to carry on all pre-disease performance without restriction." * 1 indicates that a participant is "restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work." * 2 indicates that a participant is "ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours." * 3 indicates that a participant is "capable of only limited selfcare, confined to bed or chair more than 50% of waking hours." * 4 indicates that a participant is "completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair." * 5 indicates that a participant is "dead". Mean ECOG performance status scores are calculated for the number of participants with data available.
Time frame: From Baseline (Day 1) through to End of treatment (up to Week 26) (9 time points)
The first participant was enrolled on the 18 Dec 2013 (first dose taken on the 19 Dec 2013 received) and the last participant completed the trial on the 03 May 2016 (last dose taken on the 12 Apr 2016). All participants in this trial completed the maintenance period in the KF6005/07 (NCT01964378) trial.
| Milestone | Cebranopadol |
|---|---|
| Started | 76 |
| Completing the titration phase | 67 |
| Completing the treatment | 39 |
| Completed | 38 |
| Not completed | 38 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Cancer progression | 2 |
| Withdrew: Withdrawn as forbidden meds required | 1 |
| Withdrew: Adverse event | 8 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Inclusion/exclusion criteria not met | 5 |
| Withdrew: Death | 10 |
The safety of cebranopadol was assessed by the number of participants with treatment emergent adverse events (TEAEs). A TEAE was any adverse event that occurred after the first administration of investigational medicinal product (IMP), i.e., cebranopadol in this study. In addition, pretreatment adverse events which worsened during the treatment period were also considered TEAEs.
| Participants | Cebranopadol |
|---|---|
| Number of Participants With Treatment Emergent Adverse Event (TEAEs) | 64 |
A Treatment Emergent Adverse Event (TEAE) was defined as any Adverse Event (AE) that occurred on or after the first intake of cebranopadol or a pretreatment AE which worsened during the treatment period. TEAEs were classified by the investigator as falling into 1 of 3 categories: Mild: Signs and symptoms that can be easily tolerated. Symptoms can be ignored and disappear when the participant is distracted. Moderate: Symptoms cause discomfort but are tolerable; they cannot be ignored and affect concentration. Severe: Symptoms which affect usual daily activity. For TEAE where the intensity changed over time, the maximum intensity observed during the whole duration of the adverse event was documented.
| Number of TEAEs | Cebranopadol |
|---|---|
| Mild intensity | 242 |
| Moderate intensity | 300 |
| Severe intensity | 119 |
Participants were asked "Please rate your pain by selecting the one number that best describes your pain on average during the last week." and scored their average pain intensity during the last week of the treatment period on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The absolute change from baseline for the average pain intensity during the last week was determined for all participants that scored their pain intensities. A mean value for all participants was calculated.
| units on a scale | Cebranopadol |
|---|---|
| Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period | 0.8 ± 2.14 |
The outcome of a TEAE was classified into 1 of the following 6 categories by the investigator, i.e. * Recovered/Resolved. * Recovered/Resolved with sequelae. * Fatal * Recovering/Resolving. * Not recovered/Not resolved. * Unknown (e.g., because the participant is lost to follow up).
| Number of TEAEs | Cebranopadol |
|---|---|
| Recovered/resolved | 349 |
| Recovered/resolved with sequelae | 11 |
| Not recovered/not resolved | 260 |
| Recovering/resolving | 14 |
| Fatal | 11 |
| Unknown | 16 |
The median time, in days, from the start of the open-label cebranopadol treatment to the start day of the treatment emergent adverse event (TEAE).
| days | Cebranopadol |
|---|---|
| Time to Onset of Treatment Emergent Adverse Events (TEAEs) | 53.0 (19 to 106) |
An adverse event is any untoward medical occurrence attributed to cebranopadol. Duration of Adverse Event was calculated as stop date minus start date plus 1 for non-missing and partial dates.
| days | Cebranopadol |
|---|---|
| Duration of Treatment Emergent Adverse Events (TEAEs) | 9.0 (3 to 27) |
The causality of TEAEs was assessed by the investigator as falling into 1 of the following 7 categories: Conditional/Unclassified, Unassessable/Unclassifiable, Not related, Unlikely, Possible, Probable/likely, or Certain. The numbers of TEAEs per category are presented.
| Number of TEAEs | Cebranopadol |
|---|---|
| Certainly Related | 0 |
| Possibly Related | 42 |
| Probably/Likely Related | 7 |
| Unlikely Related | 37 |
| Not Related | 574 |
| Unassessable/Unclassifiable | 1 |
| Conditional/Unclassifiable | 0 |
The countermeasure of a Treatment Emergent Adverse Event (TEAE) was classified by the investigator as being a study medication-related countermeasure and based on non-study medication countermeasures. Non-study medication related countermeasures were categorized as being one of the following: No countermeasure given; A newly started medication or change in dose or route of application of a concomitant medication due to the AE; Other countermeasures, e.g., physical therapy, surgery. Study medication-related countermeasures were categorized as being one of the following: Dose not changed; Dose reduced; Drug interrupted; Trial discontinuation. Absolute numbers are per category reported.
| Number of TEAEs | Cebranopadol |
|---|---|
| No countermeasure | 361 |
| Newly started medication | 281 |
| Other | 19 |
| Cebranopadol dose not changed as countermeasure | 595 |
| Cebranopadol dose reduced | 5 |
| Cebranopadol treatment interrupted | 14 |
| Cebranopadol withdrawn | 23 |
| Cebranopadol to dosing missing | 24 |
Only participants with TEAEs which were assessed by the investigator as falling into one of the 3 categories of causality (Possible, Probable/likely, or Certain) were summarized. The initial breakdown planned based on intensity, outcome, time to onset, duration, and countermeasures was not performed and is therefore not reported.
| Participants | Cebranopadol |
|---|---|
| Participants with related TEAEs | 20 |
| Participants with related serious TEAEs | 1 |
| Participants without related TEAEs | 55 |
The C-SSRS was administered by a clinician who had been certified to administer the C-SSRS at each visit. Suicidal ideation is classified on a 5-item scale (where 1 = Wish to be dead, 2 = Non-specific active suicidal thoughts, 3 = Active Suicidal Ideation with any methods (not plan) without intent to act, 4 = Active Suicidal Ideation with some intent to act, without specific plan, 5 = Active suicidal ideation with a specific plan and intent). The number of participants with suicidal ideation at baseline is presented below for categories with at least 1 participant.
| Participants | Cebranopadol |
|---|---|
| No suicidal ideation or behaviour | 74 |
| Wish to be dead | 1 |
| Non-specific active suicidal thoughts | 1 |
The CPSI was completed by the participants. It measures 5 items, all on a 100-mm visual analog scale: Participant's assessment of Sleep Problem Index subscores and need for sleep medication (the lower the score the better): (1) Trouble falling asleep (0 = never; 100 = always); (2) Needing sleep medication to help fall asleep (0 = never, 100 = always); (3) Awakened by pain during the night (0 = never, 100 = always); and (4) Awakened by pain in the morning (0 = never, 100 = always). The Sleep Problem Index is the sum of items (1), (3), and (4) with a maximum score of 100 indicating maximum sleep problems. Participant's assessment of the Overall Quality of Sleep (the higher the score the better): (5) Overall quality of sleep (0 = very poor, 100 = excellent).
| units on a scale | Cebranopadol |
|---|---|
| Baseline - Trouble falling asleep | 10.0 ± 18.00 |
| End of Treatment - Trouble falling asleep | 11.7 ± 22.91 |
| Baseline - Need for sleep medication | 9.2 ± 24.93 |
| End of Treatment - Need for sleep medication | 10.7 ± 28.53 |
| Baseline - Woken up by pain during night | 12.5 ± 21.02 |
| End of Treatment - Woken up by pain during night | 15.3 ± 26.36 |
| Baseline - Woken by pain in the morning | 12.6 ± 20.71 |
| End of Treatment - Woken by pain in the morning | 17.5 ± 28.21 |
| Baseline - Overall quality of sleep | 74.0 ± 27.91 |
| End of Treatment - Overall quality of sleep | 71.3 ± 30.97 |
| Baseline - Sleep Problem Index | 35.0 ± 54.03 |
| End of Treatment - Sleep Problem Index | 44.5 ± 71.10 |
Participants were asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning during the first month of treatment (comprising Titration Weeks 1 and 2 and Maintenance Weeks 1 and 2). They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-hour average pain intensity was calculated as a mean score of these daily entries of average pain intensity for each week.
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 2.96 ± 1.890 |
| Titration Week 1 | 3.18 ± 1.795 |
| Titration Week 2 | 2.90 ± 1.838 |
| Maintenance Week 1 | 2.73 ± 1.848 |
| Maintenance Week 2 | 2.69 ± 1.843 |
Participants were asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last week." at some of the visits during the treatment period. They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The mean scores of the worst pain intensity were calculated for all participants. Results for baseline and Week 26 are presented.
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 4.3 ± 2.52 |
| End of Treatment (Week 26) | 5.1 ± 2.89 |
The number of episodes of breakthrough pain during the past week was planned to be collected. However, for some participants, the intensity of breakthrough pain for the past week has been collected instead of the incidence of breakthrough pain events. Since the values of the intensity of breakthrough pain were much higher (maximum of up to 99) than the frequency of pain events, the mean is skewed and cannot be interpreted. The median for the weekly average number of breakthrough pain episodes is less influenced by these values and is reported below.
| Weekly average number of episodes | Cebranopadol |
|---|---|
| Baseline | 1.00 (0.0 to 66.0) |
| End of Treatment (Week 26) | 1.00 (0.0 to 99.0) |
Participants with neuropathic pain (determined by the completion of the DN4 \[Douleur Neuropathique\] questionnaire at enrollment) rated their symptoms of neuropathic pain using the NPSI. Ten out of 12 questions (Q1-3, 5, 6, 8-12) are answered on an 11-point numerical scale (NRS) ranging from 0 (no symptom present) to 10 (worst imaginable). The NPSI Total Score was calculated as the sum of the 10 single items scored on the 11-point NRS divided by 100. The mean score is reported on a scale of 0 (no neuropathic pain components present) to 1 (all neuropathic pain components have the maximum imaginable intensity).
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 0.243 ± 0.1677 |
| Week 2 | 0.200 ± 0.2006 |
| Week 6 | 0.146 ± 0.1397 |
| Week 14 | 0.150 ± 0.1564 |
| Week 18 | 0.117 ± 0.1529 |
| Final Visit (Week 26) | 0.236 ± 0.2183 |
Participants answered 5 questions on the 5 dimensions of the EuroQol-5 Dimension Health Questionnaire: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D Health Status Index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1), the better the health status.
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 0.687 ± 0.2111 |
| Final Visit (Week 26) | 0.606 ± 0.3214 |
The EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant-rated scale where a single value is ticked for "Your own health state today" on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 61.9 ± 20.62 |
| Final Visit (Week 26) | 56.6 ± 21.94 |
In the PGIC, participants indicates the perceived change over the treatment period compared to their condition prior to the start of treatment. Participants are requested to choose 1 of 7 categories. Scores range from "very much improved" to "very much worse". The frequency of responses per category are provided.
| Participants | Cebranopadol |
|---|---|
| Very much improved | 5 |
| Much improved | 17 |
| Minimally improved | 15 |
| No change | 9 |
| Minimally worse | 8 |
| Much worse | 3 |
| Very much worse | 1 |
| Missing | 4 |
For the CGIC assessment, the clinician indicates the perceived change in the patient's condition over the treatment period as compared to the patient's condition prior to the start of treatment. The clinician is requested to choose 1 of 7 categories. Categories range from "very much improved" to "very much worse".
| Participants | Cebranopadol |
|---|---|
| Very much improved | 9 |
| Much improved | 25 |
| Minimally improved | 10 |
| No change | 5 |
| Minimally worse | 4 |
| Much worse | 3 |
| Very much worse | 3 |
| Missing | 3 |
Participants reported the opioid type and amount of an opioid in mg/day used to relieve their breakthrough pain over the time period in the study. The average number of units of on-demand opioid medication administered during the previous day (reported on Day 3) and during the last 3 days (reported at all other visits) were documented. The number of units of on-demand opioid medication administered during the Treatment Period is summarized descriptively over the treatment period.
| units | Cebranopadol |
|---|---|
| Day 3 | 1.08 ± 1.772 |
| Week 1 | 1.45 ± 2.396 |
| Day 11 | 1.29 ± 2.280 |
| Week 2 | 0.96 ± 1.817 |
| Day 17 | 0.64 ± 1.218 |
| Week 3 | 0.78 ± 2.126 |
| Week 4 | 0.72 ± 1.380 |
| Week 6 | 0.59 ± 1.252 |
| Week 10 | 0.51 ± 1.044 |
| Week 14 | 0.47 ± 1.174 |
| Week 18 | 0.55 ± 1.250 |
| Week 22 | 0.77 ± 1.641 |
| End of Treatment (up to Week 26) | 1.06 ± 2.397 |
For those participants, who received morphine prolonged release in the CORAL trial (KF6005/07, NCT01964378) and were, thus, switched from morphine prolonged release to cebranopadol in the CORAL XT trial, the equianalgesic doses of morphine prolonged release and cebranopadol was identified.
| Ratio | Cebranopadol |
|---|---|
| Mean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol. | 156.8 ± 58.2 |
The investigator scores the ECOG performance status for a participant on a 6-point categorical scale as follows: * 0 indicates that a participant is "fully active, able to carry on all pre-disease performance without restriction." * 1 indicates that a participant is "restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work." * 2 indicates that a participant is "ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours." * 3 indicates that a participant is "capable of only limited selfcare, confined to bed or chair more than 50% of waking hours." * 4 indicates that a participant is "completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair." * 5 indicates that a participant is "dead". Mean ECOG performance status scores are calculated for the number of participants with data available.
| units on a scale | Cebranopadol |
|---|---|
| Baseline | 1.1 ± 0.75 |
| Week 2 | 1.1 ± 0.76 |
| Week 4 | 1.1 ± 0.78 |
| Week 6 | 1.2 ± 0.74 |
| Week 10 | 1.1 ± 0.77 |
| Week 14 | 1.1 ± 0.73 |
| Week 18 | 1.2 ± 0.91 |
| Week 22 | 1.4 ± 0.82 |
| Final Visit (up to Week 26) | 1.6 ± 1.10 |
Collected over All AEs were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact occurred, i.e., date of last visit/contact (a telephone call in the case of discontinuation). Treatment emergent adverse events (TEAEs) were reported for up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow-up after the last dose).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cebranopadol | 10/76 (13.2%) | 32/76 (42.1%) | 63/76 (82.9%) |
| Event | Cebranopadol |
|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/76 |
| AnaemiaBlood and lymphatic system disorders | 3/76 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/76 |
| AstheniaGeneral disorders | 2/76 |
| ConcussionInjury, poisoning and procedural complications | 2/76 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/76 |
| Anaemia of malignant diseaseBlood and lymphatic system disorders | 2/76 |
| Superior vena cava syndromeVascular disorders | 1/76 |
| Aortic thrombosisVascular disorders | 1/76 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/76 |
| Event | Cebranopadol |
|---|---|
| AstheniaGeneral disorders | 19/76 |
| Decreased appetiteMetabolism and nutrition disorders | 17/76 |
| NauseaGastrointestinal disorders | 15/76 |
| ConstipationGastrointestinal disorders | 11/76 |
| FatigueGeneral disorders | 9/76 |
| Oedema peripheralGeneral disorders | 9/76 |
| PyrexiaGeneral disorders | 9/76 |
| HeadacheNervous system disorders | 8/76 |
| SomnolenceNervous system disorders | 8/76 |
| Back painMusculoskeletal and connective tissue disorders | 8/76 |
Participants who completed treatment in KF6005/07 started on a daily dose of 200 or 400 μg (depending on previous dose level) in KF6005/09. The treatment code from KF6005/07 was not unblinded at the time of cebranopadol treatment initiation in KF6005/09, and in this trial all participants were titrated to their optimal dose of cebranopadol.
| Age, Continuous(years) | Cebranopadol |
|---|---|
| Mean | 61.7 ± 9.81 |
| Age, Customized(Participants) | Cebranopadol |
|---|---|
| Below 18 years | 0 |
| From 18 to less than 65 years | 43 |
| From 65 to less than 85 years | 33 |
| Above 85 years | 0 |
| Sex: Female, Male(Participants) | Cebranopadol |
|---|---|
| Female | 32 |
| Male | 44 |
| Race/Ethnicity, Customized(Participants) | Cebranopadol |
|---|---|
| White | 76 |
| Region of Enrollment(participants) | Cebranopadol |
|---|---|
| Romania | 2 |
| Hungary | 2 |
| Austria | 3 |
| Belgium | 1 |
| Denmark | 2 |
| Poland | 17 |
| Slovakia | 21 |
| Bulgaria | 4 |
| Serbia | 4 |
| Germany | 20 |
| DN4 Neuropathic Pain at start of KF6005/07(participants) | Cebranopadol |
|---|---|
| DN4 positive | 21 |
| DN4 negative | 55 |
| Height(meter) | Cebranopadol |
|---|---|
| Mean | 1.684 ± 0.0844 |
| Weight(kilograms) | Cebranopadol |
|---|---|
| Mean | 72 ± 14.04 |
3 further baseline measures are reported on the registry.
Plan to share: No
Ran from Dec 2013 to primary completion in Apr 2016, 28 months.
Results were first posted in Jan 2020, 3 years 9 months after primary completion.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 28 months is above that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol